ZEB1 and familial pancreatic carcinoma: The efficiency of this strategy was validated particularly for pancreatic cancer, by demonstrating that mocetinostat reduced ZEB1 expression, upregulated expression of miR-203 and other ZEB1 targets, and sensitized undifferentiated, ZEB1-expressing cancer cells for chemotherapy.